This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming third fiscal quarter, as reported in its official company earnings materials, are above the listed amount.
Current leader
58%
58%
1 outcome
Will AbbVie Q3 Global Skyrizi net revenues be above $5.5B?
Now Gained in 24h Lost in 24hChanges are in percentage points (pp).
Latest update
SurgeMonitoring onlyThe tracked probability rose to 60%, up 14.0 percentage points from 46% in the latest observation window. No evidence-qualified public source was supplied, so this remains a monitoring note rather than a causal explanation.
Yes: 46% → 60%
+14.0 ppStory so far
Recently updatedThe tracked probability rose to 60%, up 14.0 percentage points from 46% in the latest observation window. No evidence-qualified public source was supplied, so this remains a monitoring note rather than a causal explanation.
A sourced or deterministic market update is available.
Supported by the sources below
What the evidence doesn’t settle
Nothing specific is being tracked yet.
Public sources opened for this story
No public sources are attached yet.
Odds chart
Living timeline
Observed movement
Observed probability rose from 46% to 60% (+14 percentage points), from 2026-10-21T06:01:02.792Z to 2026-10-21T06:19:22.060Z (UTC).
Editorial research is deferred. This update preserves the observed market change. The cause of the move is not established.
The measured move
Yes: 46% → 60%
Probability moved from 46% to 60% (+14 percentage points). Observations were 18 minutes 19 seconds apart: 2026-10-21 06:01:02 UTC to 2026-10-21 06:19:22 UTC.
Watch further market observations and reporting about this contract. This update has not been enrolled for editorial research.
No external sources are attached yet.
Observed movement
Observed probability fell from 59.5% to 46% (-13.5 percentage points), from 2026-10-21T05:30:29.244Z to 2026-10-21T05:47:59.199Z (UTC).
Observed movement
Observed probability rose from 44% to 59.5% (+15.5 percentage points), from 2026-10-21T05:17:25.794Z to 2026-10-21T05:30:29.244Z (UTC).
Observed movement
Observed probability fell from 51% to 43.5% (-7.5 percentage points), from 2026-10-21T02:00:28.960Z to 2026-10-21T02:17:52.020Z (UTC).
Observed movement
Observed probability rose from 48% to 52% (+4 percentage points), from 2026-10-21T01:16:29.459Z to 2026-10-21T01:30:53.499Z (UTC).
Observed movement
Observed probability fell from 56.5% to 48% (-8.5 percentage points), from 2026-10-21T01:02:39.525Z to 2026-10-21T01:16:29.459Z (UTC).
Observed movement
Observed probability rose from 53% to 58% (+5 percentage points), from 2026-10-21T00:33:00.333Z to 2026-10-21T00:49:58.701Z (UTC).
Observed movement
Observed probability fell from 67% to 53.5% (-13.5 percentage points), from 2026-10-20T23:46:35.952Z to 2026-10-21T00:01:44.863Z (UTC).
Market rules, made readable
Official descriptionRead the rules before reading the headline. Resolution wording decides the outcome, not the news.
Resolves Yes
This market will resolve to "Yes" if AbbVie's Global Skyrizi net revenues for the upcoming third fiscal quarter, as reported in its official company earnings materials, are above the listed amount.
Resolves No
Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by November 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Living timeline · 12 significant updates
Will AbbVie Q3 Global Skyrizi net revenues be above $5.5B? — probability rises to 60%
Keep exploring
Will AbbVie Q3 Global Skyrizi net revenues be above __?
PlungeWill AbbVie Q3 Global Skyrizi net revenues be above __?
SurgeWill AbbVie Q3 Global Skyrizi net revenues be above __?
PlungeWill AbbVie Q3 Global Skyrizi net revenues be above __?
SurgeWill AbbVie Q3 Global Skyrizi net revenues be above __?
PlungeWill AbbVie Q3 Global Skyrizi net revenues be above __?
SurgeWill AbbVie Q3 Global Skyrizi net revenues be above __?
PlungeWill AbbVie Q3 Global Skyrizi net revenues be above __?
PlungeWill AbbVie Q3 Global Skyrizi net revenues be above __?
SurgeWill AbbVie Q3 Global Skyrizi net revenues be above __?
PlungeWill AbbVie Q3 Global Skyrizi net revenues be above __?
SurgeWill AbbVie Q3 Global Skyrizi net revenues be above __?
PolySays is independent and is not affiliated with, endorsed by, sponsored by, or operated by Polymarket. PolySays provides informational and educational content only and does not provide financial, betting, investment, tax, or legal advice. Prediction markets involve risk, and regulatory status varies by jurisdiction.
Source market
Figures refresh periodically, not tick by tick. PolySays explains markets; it doesn’t run one or give trading advice.
View on PolymarketPolySays may earn referral rewards from Polymarket links at no added cost to you. Full disclosure.